CRIS Current Research Information System

PICCI, PIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.638
EU - Europa 3.236
AS - Asia 1.280
AF - Africa 193
SA - Sud America 13
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.370
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.619
GB - Regno Unito 907
SE - Svezia 514
IT - Italia 491
DE - Germania 467
VN - Vietnam 414
CN - Cina 390
SG - Singapore 217
IN - India 177
IE - Irlanda 167
UA - Ucraina 140
RU - Federazione Russa 131
FR - Francia 117
CH - Svizzera 101
ZA - Sudafrica 82
EE - Estonia 64
TG - Togo 58
BG - Bulgaria 49
JO - Giordania 49
CI - Costa d'Avorio 37
BE - Belgio 32
JP - Giappone 14
CA - Canada 13
FI - Finlandia 12
GR - Grecia 11
NL - Olanda 10
SC - Seychelles 9
AU - Australia 8
CL - Cile 7
PL - Polonia 7
TR - Turchia 7
BR - Brasile 5
ES - Italia 5
NG - Nigeria 5
IR - Iran 4
CR - Costa Rica 3
HR - Croazia 3
BD - Bangladesh 2
BZ - Belize 2
LB - Libano 2
NO - Norvegia 2
RO - Romania 2
UZ - Uzbekistan 2
AT - Austria 1
DK - Danimarca 1
EG - Egitto 1
EU - Europa 1
HU - Ungheria 1
LK - Sri Lanka 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 9.370
Salva come PNG Salva come JPEG
Città #
Southend 826
Fairfield 620
Chandler 520
Ashburn 389
Woodbridge 309
Wilmington 293
Houston 279
Ann Arbor 263
Seattle 261
Cambridge 238
Dong Ket 233
Princeton 229
Singapore 184
Dublin 167
Bern 92
Westminster 83
Nanjing 79
Jacksonville 78
Padova 77
Berlin 66
Lomé 58
Turin 57
Bologna 53
Amman 49
Sofia 48
Bremen 46
Saint Petersburg 44
San Diego 43
Hebei 38
Abidjan 37
Beijing 37
Falls Church 35
Brussels 32
Jinan 32
Boardman 31
Shenyang 31
Nanchang 30
Santa Clara 28
Des Moines 24
Mülheim 22
Changsha 21
Milan 21
Redmond 20
Medford 19
Dearborn 18
Tianjin 18
Florence 17
New York 16
Olalla 16
Jiaxing 14
Tokyo 13
Rome 12
Helsinki 11
London 11
Redwood City 11
San Jose 11
Zhengzhou 11
Catanzaro 10
Haikou 10
Los Angeles 10
Ningbo 10
Bühl 9
Kuban 9
Crocetta 8
Las Vegas 8
Mahé 8
Norwalk 8
Guangzhou 7
Hangzhou 7
Phoenix 7
Fuzhou 6
Ottawa 6
San Francisco 6
Taiyuan 6
Abeokuta 5
Garbagnate Milanese 5
Kilburn 5
San Venanzo 5
Toronto 5
Amsterdam 4
Cagliari 4
Chicago 4
Den Haag 4
Frankfurt am Main 4
Hefei 4
Kinde 4
Kunming 4
Mainz 4
Paris 4
Provo 4
Trieste 4
Verona 4
Warsaw 4
Bari 3
Buffalo 3
Carrara 3
Cesena 3
Francavilla Al Mare 3
Lanzhou 3
Lausanne 3
Totale 6.558
Salva come PNG Salva come JPEG
Nome #
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 212
CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone: A single-institution morphological and molecular analysis of seven cases 164
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 152
Spontaneous healing of an osteochondroma fracture. 150
CD99 Acts as an Oncosuppressor in Osteosarcoma. 150
Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. 149
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. 143
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 142
Clinical outcome of central conventional chondrosarcoma. 136
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 136
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 136
Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? 130
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 127
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 125
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients 123
A simple prognostic scoring system for non metastatic osteosarcoma of the extremity 122
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 122
Osteosarcoma follow-up: chest X-ray or computed tomography? 122
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone 120
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 118
HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma 118
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 117
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas 117
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian sarcoma group study 116
Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases 115
Abstract 3201: Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3 predicts poor prognosis and promotes cell proliferation in Ewing sarcoma 115
Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation 111
Adjiuvant treatment of high-risk adult soft tissue sarcomas: a survey by the Italian Sarcoma Group 110
Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution 110
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 108
Response to high-dose ifosfamide in patients with advanced/recurrent ewing sarcoma 107
Second malignancy in 597 patients with Ewing Sarcoma of Bone treated and a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999 105
Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy 105
Ewing sarcoma in patients over 40 years of age: A prospective analysis of 31 patients treated at a single institution 105
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 104
Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma 102
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial 102
Osteosarcoma of the pelvis: A monoinstitutional experience in patients younger than 41 years 101
Small cell osteosarcoma: Clinicopathologic, immunohistochemical, and molecular analysis of 36 cases 100
Advances in Bone Metastases Management 99
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 99
Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. 97
Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression 97
Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 patients. 96
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS) 94
Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian sarcoma group/grupo español de investigación en sarcomas randomized clinical trial: Three versus five cycles of full-dose epirubicin plus ifosfamide 94
Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant chemotherapy between 1972 and 1999 93
Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients 93
Molecular diagnosis in ewing family tumors the rizzoli experience-222 consecutive cases in four years 92
null 92
Angiosarcoma of bone: A European Muscoloskeletal Oncology Society (EMSOS) multicenter, retrospective study 92
Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans. 91
Palliative therapy for osteosarcoma. 88
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 87
Osteoblastoma-like osteosarcoma: high-grade or low-grade osteosarcoma? 86
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: An Italian Sarcoma Group Trial ISG/OS-1 85
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Grouo/Scandinavian Sarcoma Group III protocol 83
Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: The rizzoli institute experience 83
PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma 83
NVE-BEZ235 as a new therapeutic option for sarcomas. 82
Primary extraskeletal myxoid chondrosarcoma of bone: Report of three cases and review of the literature 81
CIC-DUX4 Fusion-Positive Round Cell Sarcomas of Soft Tissue and Bone: Clinicopthologic and Molecular Analysis from a Single Institution 81
FDG PET/CT IN PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY FOR LOCALIZED BONE SARCOMAS 79
Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study 79
Genetic and Molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes. 78
Epidemiology 77
Sarcomi delle parti molli. Tredici anni di esperienza dell'Istituto Ortopedico Rizzoli - Sarcomas of the soft tissues. Thirteen years of experience at the Rizzoli Orthopaedic Institute. 76
Pediatric chondrosarcomas: a retrospective review of 17 cases 76
Primary metastatic Ewing's family tumors:results of the Italian Sarcoma Group And Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. 76
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series 76
Reconstruction in the treatment of pelvic chondrosarcoma. 74
Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. 73
High-grade bone sarcomas with synchronous metastases in patients older than 40. Results of the European Bone over 40: Sarcoma Study (EURO.B.O.S.S.) 73
Primary Angiosarcoma of Bone: A Retrospective Analysis of 60 Patients From 2 Institutions 72
Evoluzione dei trattamenti integrati nei sarcomi dei tessuti molli all'Istituto Ortopedico Rizzoli 71
null 71
Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients 71
null 70
Imaging of bone tumours for the musculoskeletal oncology surgeon. 67
Dedifferentiated chondrosarcoma: preliminary results from the European Bone over 40 sarcomas study, (EURO.B.O.S.S.) 67
Osteosarcoma teleangectasico: analisi clinico-patologica di 87 casi 67
Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of bone. 67
Palliative treatment: selective arterial embolisation for bone metastases. 66
miR-494.3p expression in synovial sarcoma: Role of CXCR4 as a potential target gene 66
Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma a multi-institutional case series 65
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 64
Molecular alterations of monophasic synovial sarcoma: Loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity 61
NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas 61
Inflammation and infiltration: can the radiologist draw a line? MRI versus CT to accurately assess medullary involvement in parosteal osteosarcoma 59
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. 58
HEMANGIOENDOTELIOMA OF BONE: A REVIEW OF THE RIZZOLI EXPERIENCE 56
Platelet-derived growth factors enhance proliferation of human stromal stem cells 56
Hemangioendotelioma of Bone: a review of the Rizzoli Experience 52
Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: Implication for cell-based therapy in bone defect reconstruction 51
Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results 50
How Does the Skeletal Oncology Research Group Algorithm's Prediction of 5-year Survival in Patients with Chondrosarcoma Perform on International Validation? 50
Diagnostic utility of molecular investigation in extraskeletal myxoid chondrosarcoma: the Rizzoli experience 49
The natural history of advanced inoperable central chondrosarcoma 47
EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma 47
Whole lung irradiation after high‐dose busulfan/melphalan in ewing sarcoma with lung metastases: An Italian sarcoma group and associazione Italiana ematologia oncologia pediatrica joint study 42
Totale 9.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.053 0 59 22 137 267 237 300 322 328 157 91 133
2020/20211.460 240 91 26 67 118 55 35 92 111 80 57 488
2021/20221.916 160 56 125 136 185 123 46 139 67 176 391 312
2022/20232.258 227 283 123 300 142 144 74 142 387 69 183 184
2023/2024479 23 107 41 37 22 75 40 40 14 26 23 31
2024/2025316 106 210 0 0 0 0 0 0 0 0 0 0
Totale 9.635